|1.||Rephaeli, Ada: 9 articles (01/2008 - 11/2002)|
|2.||Nudelman, Abraham: 9 articles (01/2008 - 11/2002)|
|3.||Entin-Meer, Michal: 4 articles (01/2008 - 12/2005)|
|4.||Phillips, Don R: 4 articles (09/2006 - 05/2003)|
|5.||Cutts, Suzanne M: 4 articles (09/2006 - 05/2003)|
|6.||Tarasenko, Nataly: 3 articles (01/2008 - 09/2006)|
|7.||Gruss-Fischer, Tal: 2 articles (10/2007 - 09/2006)|
|8.||VandenBerg, Scott R: 2 articles (04/2007 - 12/2005)|
|9.||Yang, Xiaodong: 2 articles (04/2007 - 12/2005)|
|10.||Haas-Kogan, Daphne Adele: 2 articles (04/2007 - 12/2005)|
06/01/2004 - "Titan is developing AN-9 for the potential treatment of various cancers. "
01/01/1998 - "Superior anti-tumor activity was observed with the continuous exposure to AN-9 (39% in vitro response at 100 microM and 70% at 200 microM) than with the two-hour exposure (20% at 100 microM and 25% at 200 microM). "
08/19/1991 - "In vivo, AN-9, increased the survival of mice in Lewis lung carcinoma primary cancer model and significantly decreased the number of lung lesions of the animals inoculated with highly metastatic cells, but did not affect their life span. "
01/01/2004 - "Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation."
04/01/2001 - "AN-9, a butyric acid (BA) derivative, is a potent differentiating and an anti-cancer drug that induces apoptosis in HL-60 cells. "
04/01/2007 - "The data suggest that AN-9 in combination with radiation may be an effective therapy for malignant gliomas."
12/01/2005 - "Preliminary in vivo experiments using human glioma cell lines grown as xenografts in mouse flanks suggest in vivo efficacy of AN-9. "
04/01/2007 - "Relative to control and single-modality treatments, the combination of AN-9 and radiation significantly inhibited tumor growth and prolonged time to failure in mice bearing glioma xenografts. "
01/01/2008 - "In a 4T1 metastatic breast carcinoma model, AN-7 inhibited the formation of lung lesions by 76% and AN-9 by 47%, further demonstrating the greater efficacy of AN-7 compared to AN-9 (P<0.02). "
01/01/2008 - "In the sc implanted human colon carcinoma HT-29 xenograft model AN-7, exhibited superior anticancer activity compared to AN-9, as was evident by the significantly greater inhibition of tumor growth and reduction of serum CEA. "
09/01/2006 - "The prodrugs exhibited a hierarchal potency of AN-193 > or = AN-7 > AN-1 and AN-9 >> AN-10 against murine lung carcinoma (3LLD122) and human breast carcinoma (MCF-7) cell lines. "
|4.||Schizophrenia (Dementia Praecox)
11/01/2002 - "In this study, we show that 21 primary samples of acute leukemia were sensitive to the antiproliferative effects of AN-9, with a 50% inhibitory concentration (IC(50)) of 45.8 +/- 4.1 microM. "
11/01/2002 - "AN-9 induced the expression of p21 in an infant leukemia sample with 11q23 rearrangement, but not in T- or B-precursor ALL. "
11/01/2002 - "The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines."
|1.||Antipsychotic Agents (Antipsychotics)
|4.||DNA (Deoxyribonucleic Acid)
|5.||Butyric Acid (Butanoic Acid)
|6.||Histone Deacetylase Inhibitors
|9.||Messenger RNA (mRNA)
|10.||Proteins (Proteins, Gene)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)